Category Archives: Premature Ejaculation

Chinese hurdler Liu Xiang was a favorite to win Gold at the London Olympics this summer, but despite massive hype from the Chinese leading up to the games, he suffered an injury that sabotaged his medal chances. In America, his failure and perseverance was actually pretty inspiring. In China, not so much. So, instead of returning home to a hero's welcome and all kinds of state-sponsored propaganda, he gets this (via Shanghai Daily): CHINESE hurdler Liu Xiang's team may take legal action against a clinic which used a picture of the athlete on a flyer promoting a "cure" for premature ejaculation. The picture is of Liu just after he crashed into the first hurdle during the men's 110m hurdles heat at the London Olympics. The flyer, advertising Huifen Hospital in the southern city of Guangzhou doesn't say the runner is Liu but the athlete, although his face is not shown as his head is bowed, is instantly recognizable and the name "Liu" can be seen on his vest. Under the picture are the words: "Falling immediately after start! Premature ejaculation is men's unspeakable agony." WOOOOOOOO CHINA! See the rest here: Chinese sports ads are the best sports ads … Continue reading →

London, Sept 29 (ANI): Chinese hurdler Liu Xiang is reportedly suing a medical company for using his photograph to promote a drug for premature ejaculation, without taking his permission. According to the Sun, the advertisement - which shows Xiang sprawled on the track with his head bowed in shame - is captioned, "Falling down at the beginning of the race! Premature ejaculation: Man's unspeakable pain." Xiang's national manager Li Guoxiong - from Beijing's Track and Field Centre - told local media, "We will discuss this with Liu and his coach and decide how to stop this." Liu's coach Sun Haiping said that they would be studying the case and would "definitely sue the hospital if it was proved to be using Liu's picture," Shanghai Daily reported. The advertisement goes on to boast that, with the clinic's latest technology, patients can prolong their "sexual life" for 15 minutes with a simple surgical procedure. The ad has been posted on flyers and distributed all over China. (ANI) Continue reading here: Liu Xiang furious after being featured in premature ejaculation ad … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/bkts2r/premature) has announced the addition of Global Markets Direct's new report "Premature Ejaculation - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H2 2012', provides an overview of the Premature Ejaculation therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. 'Premature Ejaculation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Premature Ejaculation. - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Premature Ejaculation pipeline on … Continue reading →

Oddly enough, sleep research often focuses on individuals, even though most people sleep with a partner, pet or small child. And as anyone who has shared a bed with another living, breathing, snoring, kicking, sighing being can attest, that matters. As a sex researcher, Ive long found it curious that much of our research also focuses on individuals. There are good reasons for this (among others: concerns about biasing research by limiting it to partnered people; the expense of doubling sample size; challenges with data analyses; and difficulty recruiting and retaining partners). Yet, we need to understand the role of partners in peoples sexual experiences. The need for such research is why I was thrilled to come across a recent study of men with premature ejaculation, published in the Archives of Sexual Behavior, in which the researchers also surveyed some of the mens partners. I was also happy to see this study for personal reasons, as I once dated a wonderful man who experienced PE, and the lessons it taught me about love, sex and how people feel about their bodies were important ones. First, lets talk about PE. As you may suspect, PE is fairly common, experienced by about … Continue reading →

LONDON, September 6, 2012 /PRNewswire/ -- A newly approved treatment for men experiencing premature ejaculation (PE) was unveiled at the World Congress of Sexual Medicine in Chicago on Monday, the 27th of August 2012. (Photo: http://photos.prnewswire.com/prnh/20120906/559405 ) Dr Andy Zamar presented climax control training device and programme Prolong TM, which has been found to prolong the time to ejaculation by an average 11 fold. The device, to be used in conjunction with the start-stop technique, is: substantially cheaper than current available treatments for PE; free from side effects; provides long-term effects; and requires no prescription or medical consultations. Prolong TM was developed in 2008, after independent clinical trials in London University Teaching Hospitals in 2004, where the prototype in conjunction with the programme was compared to an active control, the Gold Standard treatment, rather than a placebo. In the trial, 61 per cent of men reported lasting 11 times longer during intercourse after using Prolong, compared to three fold improvements in 40 per cent of men who had undergone Teaching Hospital standard Psychosexual Therapy. Creator and Harley Street Psychiatrist Dr Zamar said: "Roughly 30% of men experience premature ejaculation at some point in their lives. While there are a number … Continue reading →

HUNTINGTON BEACH, Calif., Aug. 3, 2012 (GLOBE NEWSWIRE) -- via PRWEB - Considered by many physicians of sexual medicine as the leading solution for premature ejaculation, Absorption Pharmaceuticals' Promescent will be featured at the SMSNA/ISSM conference in Chicago, August 26-30. Initially introduced at the SMSNA conference in Las Vegas in November 2011, Promescent continues to gain momentum in both the medical community and with men and women in the general public wishing to increase sexual satisfaction. "Because of its effectiveness, we quickly established Promescent as the product of choice for PE by key opinion leaders of sexual medicine," says Jeff Abraham, Absorption's CEO. "We expect a lot of interest from a variety of physicians at the upcoming SMSNA/ISSM conference." There are now over 200 physicians recommending Promescent to their patients who desire to extend their ejaculatory response time. Feedback from these patients and doctors has been overwhelmingly positive. The awareness of this premier PE treatment and its proprietary technology has been further highlighted with recent media coverage that has resulted in a significant consumer response for additional information and product samples. Absorption recently increased its sales team and is currently ramping up its FDA-compliant manufacturing capacity in order to meet … Continue reading →

Ampio Pharmaceuticals, Inc. (AMPE) is showing solid up movement with a gain of 11.22% to $5.65. The company announced an agreement with India-based Syngene to create a combination product to treat both premature ejaculation and erectile dysfunction in a Phase III trial. The resulted product would be known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company`s partner Daewoong Co., which will finance and conduct the trials. Amylin Pharmaceuticals, Inc. (AMLN) added 8.83% to $30.69 and made a new 52-week high of $30.75. This morning Bristol Myers Squibb Co.(BMY) agreed to buy the company for $5.3 billion or $31 per share in cash. Following an acquisition of Amylin, analyst at Piper Jaffray issued a positive note on various biotech stocks and stated those companies would be an acquisition target. BioMarin Pharmaceutical Inc.(BMRN) climbed 1.47 (3.71%) to $41.05, Theravance Inc(THRX) added 1.77 (7.94%) at $23.99, Affymax, Inc.(AFFY) rose 0.19 (1.48%) to $13.07 and Rigel Pharmaceuticals, Inc.(RIGL) surged 0.13 (1.40%) to $9.43. Cytori Therapeutics Inc. (CYTX) extended its uptrend and rose another 9.26% to $2.95. The stock has been showing solid buying since early July and went up all the way from $2.05 to $2.95 in about … Continue reading →

Greenwood Village, CO//PRNewswire via COMTEX/ -- Ampio Pharmaceuticals, Inc. /quotes/zigman/5133505/quotes/nls/ampe AMPE +9.84% , a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane(TM) to treat PE in the USA. Vaughan Clift, MD, Ampio's Chief Regulatory Officer, noted "Contrary to rumors that the FDA did not recognize PE as a treatable ailment, the FDA has expressly adopted the definition of PE as a disease condition, using the definition of Premature Ejaculation provided by the International Society for Sexual Medicine (ISSM) Ad Hoc Committee (i.e., premature ejaculation is characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.*) This definition fully complements … Continue reading →

GREENWOOD VILLAGE, Colo., July 2, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting in June with the FDA gave the company clear guidance for the two concurrent pivotal trials necessary for approval of Zertane to treat PE in the USA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Vaughan Clift, MD, Ampio's Chief Regulatory Officer, noted "Contrary to rumors that the FDA did not recognize PE as a treatable ailment, the FDA has expressly adopted the definition of PE as a disease condition, using the definition of Premature Ejaculation provided by the International Society for Sexual Medicine (ISSM) Ad Hoc Committee (i.e., premature ejaculation is characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.*) This definition fully … Continue reading →

REUTERS - Ampio Pharmaceuticals Inc (NAQ:AMPE - News) signed a deal with Syngene, a unit of Bangalore-based Biocon Ltd (NSI:BIOCON.NS - News), to produce its experimental drug for premature ejaculation and erectile dysfunction, sending its shares up 23 percent. The combination drug, Zertane-ED, would be made by Syngene, Ampio said. Ampio's Korea-based partner Daewoong Co Ltd will finance and conduct late-stage studies in South Korea. "We will be working with Daewoong to get the study approved by the U.S. Food and Drug Administration and in South Korea, but there is no specific timeline yet," a company spokesman told Reuters. The drug would combine Ampio's experimental drug Zertane, which is being tested in a late-stage trial to treat premature ejaculation, with an erectile dysfunction drug similar to Pfizer Inc's (PFE.N) blockbuster medicine Viagra. There are currently no approved drugs in the United States to treat premature ejaculation and Ampio estimates up to 30 percent of males treated for premature ejaculation also suffer from erectile dysfunction. The biopharmaceutical company is also developing three other products to treat inflammation and eye damage due to diabetes. Shares of the company were up 11 percent at $5.68 on Monday on the Nasdaq, after soaring to … Continue reading →